Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
2011-004096-36Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in hereditary hemorrhagic telangiectasia (HHT), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Clinical improvement in epistaxis. Started Mar 2012; status: completed.
02
Drugs
thalidomide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2011-004096-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004096-36.